Germany's Allogenetics raises €3.8M to rethink organ transplants
What's the deal? AllogeneticsDealroom has a profile for this one. Try Dealroom →, a Hanover, Germany-based biotech, has raised €3.8 million in a pre-Series A round led by NBank CapitalDealroom has a profile for this one. Try Dealroom →. CARMA FUND, Life Science Valley Wachstumsfonds, and additional corporate and private investors took part.
What's the endgame? The company treats donor organs with a one-time gene therapy before transplant, aiming to stop the recipient's immune system from rejecting the graft. Its goal is to reduce graft loss while eliminating the need for lifelong immunosuppression.
Why now? The proceeds will push Allogenetics' lead program, ALG-115, through IND-enabling studies toward first-in-human lung transplantation trials, planned to start between late 2027 and early 2028.
The therapy works by knocking down expression of the antigen-presenting molecules MHC class I and II, calibrating antigen presentation so the graft evades rejection while keeping immune protection. In a pig model of lung transplantation, ALG-115 showed 8-year survival without immunosuppressants.
Between the lines: Long-term survival rates for transplant patients remain low, and lifelong immunosuppressants can cause severe side effects and place a heavy compliance burden on patients.
"By tackling key challenges in organ transplantation from a different angle, we believe our new concept has the potential to change the treatment paradigm," said chief executive officer Oliver Ernst.
NBank Capital investment manager Susanne Hauck said the company is "at an exciting inflection point, with compelling preclinical evidence backing the applicability and transformative potential of its innovative gene therapy approach."
The signal: Allogenetics' organ-side approach reframes transplant medicine around modifying the donor organ rather than suppressing the patient's immune system for life — a bet that early clinical data will now have to validate.
Read more: daily-tribune.com
Image credit: Ken Lund
